EUVIMEDEUVIMED entdecken
Crossref

Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone

Pieter Sonneveld iD, Sonja Zweegman iD, Thierry Facon iD, Vania Hungria iD, Nizar J Bahlis iD, Philippe Moreau iD, Hermann Einsele, Mario Boccadoro iD, Fredrik Borgsten, Andras Borsi, Marjorie Nobrega, Viktor Kovács und 7 weitere

Journal of Clinical Oncology · 09.11.2026

DOI: 10.1200/jco-26-00384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 09.11.2026. Verfasst von Pieter Sonneveld und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Die Arbeit nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) significantly improved progression-free survival (PFS) versus VRd in newly diagnosed multiple myeloma (NDMM) in transplant eligible (TE; PERSEUS) and transplant-ineligible (TIE; CEPHEUS) populations. Median PFS with DVRd has not been reached in either study. This analysis extrapolated PFS data from PERSEUS and CEPHEUS (TIE subgroup) to estimate long-term outcomes for DVRd. Following UK National Institute for Health and Care Excellence guidance on survival data extrapolation, seven parametric distributions were fitted to model PFS data. In PERSEUS (TE population), the projected median PFS range across distributions was 158-255 months versus 76-119 months and best-fit (exponential distribution) PFS estimates were 205 months (17.1 [range, 13.2-21.2] years, DVRd) versus 87 months (7.3 [range, 6.3-9.9] years, VRd). For CEPHEUS (TIE population), projected median PFS range across distributions was 96-118 months versus 52-54 months and best-fit estimates were 100 months (8.3 [range, 8.0-9.8] years, DVRd) versus 53 months (4.4 [range, 4.3-4.5] years, VRd). PFS projections were significantly longer with DVRd than VRd in TE (additional 118 months; 9.8 years) and TIE patients (additional 47 months; 3.9 years) across all seven distributions. These extrapolations reinforce the benefit of DVRd as standard of care in NDMM regardless of transplant eligibility.

Autor:innen und Institutionen

  • Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • European Myeloma Network, Rotterdam, the Netherlands.
  • Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • University of Lille, CHU de Lille, Lille, France.
  • Clínica Médica São Germano, São Paulo, Brazil.
  • Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.

ORCID-Profile: Pieter Sonneveld, Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J Bahlis, Philippe Moreau, Mario Boccadoro, Anna Sitthi-Amorn, Meletios A Dimopoulos, Paula Rodríguez-Otero, Saad Z Usmani

Zitieren

APA

Sonneveld, P., Zweegman, S., Facon, T., Hungria, V., Bahlis, N. J., Moreau, P., Einsele, H., Boccadoro, M., Borgsten, F., Borsi, A., Nobrega, M., Kovács, V., Wang, J., Rowe, M., Sitthi-Amorn, A., Carson, R. L., Dimopoulos, M. A., Rodríguez-Otero, P., & Usmani, S. Z. (2026). Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00384

Vancouver

Sonneveld P, Zweegman S, Facon T, Hungria V, Bahlis NJ, Moreau P, et al. Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00384

BibTeX
@article{Sonneveld2026,
  author = {Sonneveld, Pieter and Zweegman, Sonja and Facon, Thierry and Hungria, Vania and Bahlis, Nizar J and Moreau, Philippe and Einsele, Hermann and Boccadoro, Mario and Borgsten, Fredrik and Borsi, Andras and Nobrega, Marjorie and Kovács, Viktor and Wang, Jianping and Rowe, Melissa and Sitthi-Amorn, Anna and Carson, Robin L and Dimopoulos, Meletios A and Rodríguez-Otero, Paula and Usmani, Saad Z},
  title = {Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00384}
}
Kostenlos starten →